



Pharmacist Impact on Prescription Assistance Programs Within a Medically Underserved Primary Care Clinic

Paige Collick, PharmD, MBA
PGY-1 Pharmacy Resident, CoxHealth
MSHP Missouri Resident Research Conference
June 5, 2020



Disclosure Statement


- The speaker has no actual or potential conflict of interest in relation to this presentation.

Learning Objective

- Identify pharmacist role with prescription assistance programs to help improve patient care in underserved populations

Lack of Health Insurance

- In 2017, ~28.5 million Americans did not have health insurance and had limited access to prescription medications.



Impact of Prescription Assistance Programs (PAPs)

Furl et al.

- HIV clinic: those who obtained insurance were more likely to have undetectable HIV viral load

Burley et al.

- ~47% decline in rate of emergency department (ED) and hospital visits in patients who were enrolled into a PAP by a social worker

Sarrafizadeh et al.

- \$1000 cost savings per patient per year who were enrolled in PAPs

Furl. *BMC Infect. Dis.* 2018;18(1):132

Burley. *J Manag Care Spec Pharm.* 2016;22(4):381-387

Sarrafizadeh. *Am J Health Syst Pharm.* 2004;61(17):1816-1820

Pharmacist Role

Focused in
specialty clinics

Enroll patients
into PAPs

Provide
medication
management
services

- A decrease in hemoglobin A1C, blood pressure, and cholesterol values post-enrollment into PAPs with pharmacist involvement.



Purpose

To assess the impact of a pharmacist working under a collaborative practice agreement (CPA) on prescription assistance programs (PAPs) within a medically underserved clinic

CoxHealth Overview

- Locally owned, not-for-profit health system established in 1906
- Six hospitals, over 80 physician clinics
- >1,000,000 clinic visits annually



Family Medical Care Center (FMCC)

Primary care clinic serving uninsured and underinsured patients

Led by 16 faculty providers and 27 medical residents

CoxHealth Medication Access Program (CMAP) helps patient enroll in PAPs

Primary Objective

Review the rate of hospitalizations and emergency department (ED) visits in patients enrolled in a PAP, one-year pre-pharmacist CPA initiation and up to one-year post-pharmacist CPA initiation.

Secondary Objectives

Review disease state control pre- and post- pharmacist CPA initiation

Quantify medication therapy management (MTM) interventions completed by pharmacist

Classify drugs obtained through PAPs by pharmacist

Estimate price of drugs obtained through PAPs by pharmacist

Compare adherence rates pre-and post- pharmacist CPA initiation

Study Design

- Single center, retrospective chart review



- Institutional Review Board (IRB) approved this study in October 2019

Study Population


Inclusion Criteria

- Patients without any form of insurance or prescription drug coverage
- Enrolled in CMAP at FMCC from 06/01/2017 through 06/01/2019
- PAPs managed by pharmacist under CPA

Exclusion Criteria

- Pregnant patients
- Patients under 18 years of age
- Patients who transferred care outside of FMCC
- Hospitalizations and ED visits that were a result from trauma

Methods



Baseline Characteristics

n = 106	
Age (years), mean (range)	45 (19-65)
Male, no. (%)	43 (40.6)
Resident Provider, no. (%)	58 (54.7)
Faculty Provider, no. (%)	29 (27.4)
Midlevel Provider, no. (%)	19 (17.9)
Obtained Insurance, no. (%)	16 (15.1)
CMAP prior to CPA, no. (%)	30 (28.3)

Baseline Co-morbidities

n = 106	
Diabetes, no. (%)	44 (41.5)
Depression, no. (%)	24 (22.6)
Hypertension, no. (%)	23 (21.7)
Asthma, no. (%)	22 (20.8)
COPD, no. (%)	12 (11.3)
Smoker, no. (%)	10 (9.4)
Hypothyroidism, no. (%)	6 (5.7)
Hyperlipidemia, no. (%)	5 (4.7)
Hepatitis C, no. (%)	4 (3.8)

Results



Primary Objective

	Pre-CPA	Post-CPA	Percent Change	P-value (α = 0.05)
Hospitalizations, no.	42	25		
Hospitalizations per person (n=106)	0.40	0.24	-40.5%	0.113
ED visits, no.	114	77		
ED visits per person (n=106)	1.08	0.73	-32.5%	0.011

Pharmacist Interventions

- Total of 515 interventions, ~5/person (n=106)

CMAP medication
check in

Medication
changes

Diabetes consults

Medication
recommendations

Patient counseling

Status updates on
CMAP process

Medication
reconciliation

Lab
recommendations

Appointment
recommendations

Disease State Control


Value	Pre CPA Mean \pm SD	Post CPA Mean \pm SD	P-value ($\alpha = 0.05$)
Hgb A1c (% , n=38)	9.8 \pm 1.6	8.7 \pm 2.2	0.005
Systolic BP (mmHg, n=23)	144 \pm 27	134 \pm 12	0.069
Diastolic BP (mmHg, n=23)	85 \pm 16	80 \pm 12	0.17
FEV1/FVC (n=2)	0.70 \pm 0.21	0.72 \pm 0.03	0.903
TSH (mIU/mL, n=5)	29.13 \pm 55.21	3.09 \pm 3.34	0.36
PHQ-9 (n=8)	18 \pm 7	16 \pm 9	0.36
HCV Viral Load (IU/mL, n=3)	518K \pm 581K	<15 \pm 0	0.26

Brand Drugs Obtained by Pharmacist

Abilify [®]	Advair [®]	Basaglar [®]	Breo [®]	Bydureon [®]
Cialis [®]	Coreg CR [®]	Cymbalta [®]	Dexilant [®]	Eliquis [®]
Entresto [®]	Harvoni [®]	Humalog [®]	Imitrex [®]	Invokamet [®]
Janumet [®]	Lamictal [®]	Lantus [®]	Maxalt [®]	Nasonex [®]
Novolog [®]	Pristiq [®]	ProAir [®]	Prozac [®]	Pulmicort [®]
Rexulti [®]	Symbicort [®]	Synthroid [®]	Synvisc-One [®]	Toujeo [®]
Trulicity [®]	Ventolin [®]	Xarelto [®]	Zyclara [®]	Zyprexa [®]

Cost of Drugs

- Total cost of drugs obtained by pharmacist during study period (n=106): \$683,779.96
- Cost per person: \$6,450.75
- Example:



Adherence Rates

Mean MPR Pre-CPA:
95.23% (SD 6.22)

○ n=30



Mean MPR Post-CPA:
85.12% (SD 20.4)

○ p-value = 0.003

Limitations

Full year prior to CPA-signed and/or full year after CPA-signed not available for every patient

Adherence rates are based on charting in EMR

PAPs cause delays in shipment

Diagnostic labs not completed

Future Directions

Additional disease state consults

- Hypertension
- Asthma
- COPD

Conclusion



With ~5 pharmacist interventions per patient, pharmacist impact on PAPs shows a significant decrease in ED visits



Lack of lab data makes it hard to determine disease state control



With pharmacists able to sign for PAPs, drug cost savings for patients is ~\$6450 per patient per year



Acknowledgements

- Cassie Heffern, PharmD, BCACP
- Chelsea Landgraf, PharmD, BCPS, BCACP
- Karrie Derenski, PharmD, BCCCP, BCNSP, CNSC

References

- Berchick ER, Hood E, Barnett JC. Health Insurance Coverage in the United States: 2017. United States Census Bureau. September 12, 2018. Available from: [Census.gov](https://www.census.gov). Accessed August 11, 2019.
- Burley MH, Daratha KB, Tuttle K, et. al. Connecting Patients to Prescription Assistance Programs: Effects on Emergency Department and Hospital Utilization. *J Manag Care and Spec Pharm*. 2016;22(4):381-387.
- Chisholm MA, Spivey CA, Mulloy LL. Effects of a medication assistance program with medication therapy management on the health of renal transplant recipients. *Am J Health Syst Pharm*. 2007;64(14):1506-1512.
- Chisholm MA, Vollenweider LJ, Mulloy LL, Wynn JJ, Wade WE, Dipiro JT. Cost-benefit analysis of a clinical pharmacist-managed medication assistance program in a renal transplant clinic. *Clin transplant*. 2000;(4):304.
- Furl R, Watanabe-Galloway S, Lyden E, Swindell S. Determinants of facilitated health insurance enrollment for patients with HIC disease, and impact of insurance enrollment on targeted health outcomes. *BMC Infect Dis*. 2018;18(1):132.
- Glied S. Healthcare Crisis: Who's at Risk? The Uninsured. PBS. Available from: <https://www.pbs.org/healthcarecrisis/uninsured.html>. Accessed Sept. 3, 2019.
- Key Facts about the Uninsured Population. KFF Henry J Kaiser Family Foundation. December 7, 2018. Available from: https://www.kff.org/uninsured/fact-sheet/key-facts-about-the-uninsured-population/#endnote_link_384995-27. Accessed Sept. 3, 2019.
- Sagall RJ. Pharmaceutical companies helping patients get their medicines. NeedyMeds. Available from: <https://www.needymeds.org/pap>. Accessed Sept. 3, 2019.
- Sarrafizadeh M, Waite NM, Hobson EH, Migden H. Pharmacist-facilitated enrollment in medication assistance programs in a private ambulatory care clinic. *Am J Health Syst Pharm*. 2004;61(17):1816-1820.



Pharmacist Impact on Prescription Assistance Programs Within a Medically Underserved Primary Care Clinic

Paige Collick, PharmD, MBA
PGY-1 Pharmacy Resident, CoxHealth
Midwest Pharmacy Residents Conference
May 7, 2020